Compare Immunovant Inc. Common Stock (IMVT) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 3.8× Immunovant Inc. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| IMVT | RPRX | |
|---|---|---|
Market Cap | $6.62B | $25.27B |
Volume | 1,131,364 | 3,671,183 |
Sector | Health | Health |
52-Week High | $44.96 | $63.96 |
52-Week Low | $17.03 | $35.44 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.72B | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
